Patents by Inventor Kim M. Keeling

Kim M. Keeling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210244738
    Abstract: Disclosed herein are methods of treating or preventing a disease caused by nonsense mutations, or ameliorating one or more symptoms associated therewith, that involve administering to a patient in need thereof a therapeutically or prophylactically effective amount of triamterene, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug, or polymorph thereof.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 12, 2021
    Inventors: David M. Bedwell, Kim M. Keeling, Ming Du, Steven M. Rowe, Venkateshwar Mutyam, Amna Siddiqui, James Robert Bostwick
  • Patent number: 10960018
    Abstract: The present disclosure provides compositions and methods for treating and/preventing diseases and conditions associated with premature termination mutations. The methods disclosed herein comprise the step of administering to the subject a therapeutically effective dose of a compound described herein that induces read-through of the premature termination codon. The methods of the present disclosure may further comprise treating the subject with enzyme replacement therapy wherein the enzyme replacement therapy is selected for the disease or condition to be treated. Furthermore, the present disclosure provides method of pharmacologically suppressing premature termination codons in a subject in need of such suppression.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 30, 2021
    Assignee: The UAB Research Foundation
    Inventors: Steven Rowe, David M. Bedwell, Venkateshwar Mutyam, Ming Du, Kim M. Keeling
  • Publication number: 20190125775
    Abstract: The present disclosure provides compositions and methods for treating and/preventing diseases and conditions associated with premature termination mutations. The methods disclosed herein comprise the step of administering to the subject a therapeutically effective dose of a compound described herein that induces read-through of the premature termination codon. The methods of the present disclosure may further comprise treating the subject with enzyme replacement therapy wherein the enzyme replacement therapy is selected for the disease or condition to be treated. Furthermore, the present disclosure provides method of pharmacologically suppressing premature termination codons in a subject in need of such suppression.
    Type: Application
    Filed: April 17, 2017
    Publication date: May 2, 2019
    Inventors: Steven ROWE, David M. BEDWELL, Venkateshwar MUTYAM, Ming DU, Kim M. KEELING
  • Patent number: 7749971
    Abstract: The present invention provides a method of treating lysosomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically effective dose of an aminoglycoside. In addition, this method may further comprise treating the individual with enzyme replacement therapy. Furthermore, the present invention provides method of pharmacologically suppressing premature stop mutations in an individual with these lysosomal storage diseases, comprising the step of administering to said individual a pharmacologically effective dose of an aminoglycoside.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: July 6, 2010
    Inventors: David M. Bedwell, Kim M. Keeling